Clinical Trials

41 enrolled

Pancreatic Neoplasms

NCT04557020 2024-05-01

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

200 enrolled

Nasopharyngeal Carcinoma

NCT04739670 2024-03-01

BELLA

31 enrolled

Recurrence, Triple Negative Breast Neoplasms

NCT05626101 2024-02-13

Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

Phase NA Unknown

280 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05189028 2024-02-06

Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer

290 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06211881 2024-01-18

Chi-GVM Regimen for the Treatment of R/R PTCL

Phase NA Unknown

50 enrolled

Phase EARLY_PHASE1 Unknown

Lymphoma, T-Cell, Peripheral

NCT06204614 2024-01-12

Drug Screening Using IMD in Bladder Cancer

18 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT02098954 2023-12-27

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05580445 2023-11-22

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

114 enrolled

Advanced Pancreatic Cancer

NCT04324307 2023-09-01

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

60 enrolled

Pancreatic Neoplasms

NCT04902261 2023-09-01

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

140 enrolled

Pancreatic Neoplasms

NCT05415917 2023-08-22

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

75 enrolled

Pancreatic Neoplasms

NCT04522050 2023-07-12

Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Phase 1 Unknown

65 enrolled

Nasopharyngeal Carcinoma

NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Phase NA Unknown

34 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

NCT05795920 2023-04-03

Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer

92 enrolled

Pancreatic Neoplasms

NCT01405586 2023-03-24

MILES-3

299 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01656551 2023-03-24

MILES-4

232 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01802749 2023-03-24

MITO16MANGO2b

406 enrolled

Gynecologic

Ovarian Neoplasms

NCT05774028 2023-03-17

Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT05723991 2023-02-13

Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

Phase 4 Unknown

36 enrolled

Carcinoma, Transitional Cell

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT05701332 2023-01-27

Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume

Phase 4 Unknown

25 enrolled

Fibrosis, Oligospermia

NCT05672537 2023-01-05

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

70 enrolled

Cholangiocarcinoma

NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

40 enrolled

Resectable Biliary Tract Cancer

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05634564 2022-12-05

Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer

62 enrolled

Pancreatic Neoplasms

NCT05350943 2022-10-18

HAIC Combined With Toripalimab and Donafenib for Advanced BTC

70 enrolled

Biliary Tract Adenocarcinoma

NCT05410197 2022-10-12

Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

43 enrolled

Advanced Biliary Tract Cancer

NCT00997906 2022-09-29

Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC

Phase 2/3 Unknown

172 enrolled

Head and Neck Neoplasms

NCT03487016 2022-09-08

FOOTPATH

270 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT05401279 2022-08-18

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

20 enrolled

Urothelial Carcinoma Bladder

NCT05466318 2022-07-25

ChiCGB vs BEAM in High-risk or R/R Lymphomas

306 enrolled

Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04297267 2022-07-22

nonpCR GP

100 enrolled

Triple Negative Breast Neoplasms

NCT05448885 2022-07-08

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

50 enrolled

Nasopharyngeal Carcinoma

NCT05448183 2022-07-07

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

45 enrolled

Cholangiocarcinoma

NCT05441761 2022-07-01

Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL

60 enrolled

Lymphoma, T-Cell, Peripheral

NCT04401709 2022-06-15

Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer

490 enrolled

Biliary Tract Neoplasms

NCT02341911 2022-04-20

TNBC

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT05298020 2022-03-28

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

20 enrolled

Advanced Pancreatic Cancer

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

54 enrolled

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT03366415 2022-03-04

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

420 enrolled

Nasopharyngeal Carcinoma

NCT04617821 2022-01-28

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

300 enrolled

Borderline Resectable Pancreatic Cancer

NCT05185869 2022-01-11

SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer

58 enrolled

Pancreatic Neoplasms

NCT05030077 2021-09-01

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

53 enrolled

Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

427 enrolled

Gynecologic

Ovarian Neoplasms

NCT04586465 2021-08-24

DYNAPET

23 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04961970 2021-07-14

HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

188 enrolled

Cholangiocarcinoma

NCT04917250 2021-06-08

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

15 enrolled